Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Director operating in the Biopharma space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Vincenzo Garzya
Patient Centricity Excellence Director of AstraZeneca
Follow Vincenzo Garzya:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Claus Bendtsen
Executive Director of AstraZeneca
Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, mathematical modelling, image analytics and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.
Follow Claus Bendtsen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Amir Zur
Sr. Director, Head of Products of Digital Health of Teva Pharmaceutical Industries
Amir Zur is a Sr. Director, Head of Products of Digital Health in Teva Pharmaceuticals, Mr. Zur leads the digital products roadmap, development life-cycle and quality to build Drug-Device Combination and Medical Device products to improve outcomes and treatments to patients. Previously at Teva, he led the teams who built a novel innovative product from scratch and established digital foundations, processes and transformation in the company. The product was recently approved by the FDA as the first of its kind in respiratory and in the entire Health industry. During his career Amir held vast leadership roles as an executive manager for more than 20 years in the digital industry both global large and small companies.
Follow Amir Zur:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Ray Edgson
Director of evonetix
Follow Ray Edgson:
About evonetix: Evonetix is a provider of a desktop platform designed to synthesize DNA at unprecedented accuracy and scale.
David Brown
Co-Founder and Chairman of the Board of Directors of Healx
David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia. David subsequently co-founded antibody company Crescendo Biologics and serves on the boards of Healx Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He is a Trustee (Director) of two charities, Antibiotic Research UK, dedicated to solving the looming problem of antibiotic resistance; and Friends of Manjushree Vidyapith School and Orphanage, a charity he co-founded in 2005 to help destitute orphans in South Tibet.
Follow David Brown:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Ian Roberts
Director of Therapeutic Technology of Healx
As senior investigator at the MRC Cancer Cell Unit, Cambridge, Ian lead the development of molecular cytogenetic and genomics approaches for the discovery of disease genes in small round blue cell tumours, and cervical carcinoma. During this time Ian developed algorithms for copy number imbalance analysis and integration with expression data using array based techniques. Following a move to industry, as Head of Informatics at Population Genetics Technologies Ltd Ian lead the development of Next Generation DNA Sequencing (NGS) variant discovery pipelines. Ian continued to develop NGS based variant discovery workflows as Senior Bioinformatician at 14M Genomics, before joining Healx in 2016.
Follow Ian Roberts:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Catherine Beech
Board of Directors of Exonate
Follow Catherine Beech:
About : Exonate is a biotech company spun out of the University of Nottingham that is focused on alternative splicing of (VEGF) in ophthalmology.
Richard Saumarez
Director of Fen EP Limited
Follow Richard Saumarez:
About Fen EP Limited: Fen EP Limited is a developer of biomedical device created to prevent sudden cardiac death.
Richard Saumarez
Director of Fen EP Limited
Follow Richard Saumarez:
About Fen EP Limited: Fen EP Limited is a developer of biomedical device created to prevent sudden cardiac death.
